Wladimir Hogenhuis Purchases 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were bought at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the acquisition, the director now directly owns 77,267 shares of the company’s stock, valued at approximately $363,154.90. This trade represents a 14.87 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Rezolute Trading Down 2.2 %

NASDAQ RZLT opened at $4.53 on Friday. The firm has a market capitalization of $274.20 million, a P/E ratio of -3.71 and a beta of 1.10. The business has a fifty day simple moving average of $4.84 and a 200 day simple moving average of $4.90. Rezolute, Inc. has a 12 month low of $1.49 and a 12 month high of $6.19.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. As a group, sell-side analysts predict that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Rezolute

Several hedge funds have recently modified their holdings of RZLT. Alpine Global Management LLC bought a new position in shares of Rezolute in the fourth quarter valued at approximately $54,000. Woodline Partners LP lifted its holdings in Rezolute by 2,817.1% during the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company’s stock worth $5,338,000 after acquiring an additional 1,052,002 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its position in Rezolute by 48.5% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock worth $97,000 after purchasing an additional 6,470 shares during the last quarter. Point72 Europe London LLP bought a new position in Rezolute in the 4th quarter valued at $720,000. Finally, Man Group plc purchased a new stake in shares of Rezolute during the 4th quarter valued at $425,000. Institutional investors own 82.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Wedbush reiterated an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a report on Monday, November 4th. JMP Securities boosted their price target on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research note on Thursday, February 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $24.38.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.